NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01320280 2022-07-01BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate CancerUniversitätsklinikum Hamburg-EppendorfPhase 2 Terminated29 enrolled